Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences presented positive results from its Phase 1a clinical trial of PMN310, an investigational monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease, at the 17th CTAD Conference. The trial, involving 40 healthy volunteers across five dose cohorts (2.5-40 mg/kg), demonstrated that PMN310 was generally well-tolerated and effectively crossed the blood-brain barrier. The pharmacokinetic data suggests monthly dosing could provide adequate levels for target engagement in AD patients. Based on these results, the company plans to initiate a 12-month Phase 1b trial in 100 patients with mild cognitive impairment due to AD and early AD by year-end 2024.

ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's disease treatment, highlighting its enhanced selectivity for toxic amyloid-beta oligomers (AßO). Key findings show:

1. PMN310 demonstrates little to no interaction with monomers
2. It's minimally impacted by excess monomer competition in binding to toxic oligomers
3. PMN310 doesn't bind to Aß plaque or vascular deposits

These characteristics could potentially reduce the risk of amyloid-related imaging abnormalities (ARIA). ProMIS recently reported positive topline data from the first four cohorts in its Phase 1a trial of PMN310, meeting objectives for tolerability, safety, and pharmacokinetics. The company plans to advance PMN310 into a Phase 1b study in Q4 2024.

ProMIS Neurosciences (Nasdaq: PMN), a biotechnology company focused on developing therapeutics for neurodegenerative diseases, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Neil Warma will present an overview of the company's antibody therapeutics targeting toxic misfolded proteins in diseases like Alzheimer's, ALS, and multiple system atrophy.

Key points:

• Presentation available on-demand from September 9, 2024, at 7:00 a.m. ET
• One-on-one meetings with investors scheduled for September 9-10, 2024
• Replay accessible for at least 30 days on the company's website

This event provides an opportunity for ProMIS to showcase its innovative approach to treating neurodegenerative diseases to potential investors and industry professionals.

ProMIS Neurosciences (Nasdaq: PMN) reported positive topline data from its Phase 1a clinical trial of PMN310 for Alzheimer's disease, meeting objectives for tolerability, safety, and pharmacokinetics. The company secured up to $122.7 million in private placement financing to advance the Phase 1b study in the second half of 2024. Key highlights include:

1. PMN310 was well-tolerated with no serious adverse events in the first four cohorts.
2. The drug crossed into the central nervous system in quantities suggesting potential target engagement.
3. PMN310's selectivity could differentiate it in efficacy and safety profile.
4. The upcoming Phase 1b trial will enroll 100 patients and measure important clinical endpoints over 12 months.
5. Q2 2024 financials show cash and equivalents of $1.0 million, with R&D expenses at $1.6 million and a net loss of $2.6 million.

ProMIS Neurosciences (Nasdaq: PMN) announced the publication of two papers highlighting the role of toxic misfolded superoxide dismutase-1 (SOD1) aggregates in the pathogenesis of amyotrophic lateral sclerosis (ALS). The research, published in Acta Neuropathologica and Open Biology, supports targeting misfolded proteins as a therapeutic strategy for ALS.

Key findings include:

• SOD1 aggregates are present in both familial and sporadic ALS neural tissues
• A previously underappreciated SOD1 amyloidogenic region in β-strand II and III is important for aggregation and toxicity
• The existence of measurable SOD1 seeds across different forms of ALS contributes to the fundamental understanding of the disease

ProMIS is developing PMN267, an antibody targeting toxic misfolded TDP-43, as a potential ALS therapeutic. The research reinforces the company's broader strategy of targeting misfolded proteins in neurodegenerative diseases.

ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company specializing in therapeutics for neurodegenerative diseases, has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The company's representatives, Neil Warma (interim CEO) and Dr. Larry Altstiel (Chief Medical Officer), will engage in a fireside chat on August 6, 2024, at 12:00 p.m. ET.

ProMIS Neurosciences focuses on developing treatments targeting toxic misfolded proteins, which are associated with various neurodegenerative conditions. The fireside chat will be available via live webcast to conference attendees, providing an opportunity for investors and industry professionals to gain insights into the company's progress and future plans.

ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricted conformational B cell epitopes as vaccine candidates. Vaccination with these epitopes produced strong antibody responses without measurable pro-inflammatory T cell responses against Aβ. Notably, immunization with epitope 301, the target of PMN310, alone was sufficient to produce maximal reactivity against brain AβO.

The study suggests that ProMIS' approach could potentially lead to an AD vaccine capable of inducing an effective antibody response against pathogenic Aβ. This vaccine could be administered as a preventative measure to at-risk individuals or given therapeutically to diagnosed patients to inhibit AD progression.

ProMIS Neurosciences (Nasdaq: PMN) has reported positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310 in healthy volunteers for Alzheimer's disease. The results showed:

• A favorable safety profile and tolerability across four ascending dose levels
• Dose-dependent levels of PMN310 antibody in cerebrospinal fluid (CSF)
• Potential for target engagement in Alzheimer's patients

PMN310 was well-tolerated with no serious adverse events observed. The antibody demonstrated dose proportionality in CSF and a half-life of approximately 25 days, supporting monthly dosing. ProMIS plans to advance PMN310 into a Phase 1b study in Alzheimer's patients in the second half of 2024.

ProMIS Neurosciences (Nasdaq: PMN) has announced a private placement financing of up to $122.7 million. The deal includes an upfront $30.3 million and potential additional $92.4 million from warrant exercises. The financing involves issuing Common Share Units and Pre-Funded Units at $2.15 and $2.14 per unit, respectively. Each unit includes various warrants with different exercise prices and expiration conditions.

The funds will support the development of PMN310, ProMIS' lead antibody therapeutic for Alzheimer's disease. The financing is expected to close on July 31, 2024, subject to conditions. Notable investors include Great Point Partners, Armistice Capital, and Ally Bridge Group. Guggenheim Securities led the placement, with Ceros Financial Services and Leede Financial as additional agents.